Hepatitis C Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Date : Mar 2018

Formats :
Report Code : PMR83649630

Category : Pharmaceutical and Healthcare
No Of Pages :
Global Hepatitis C Treatment Market Outline: Hepatitis C Treatment Market


The global market for Hepatitis C treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis C infection. Rising awareness regarding Hepatitis C treatment, increase in healthcare expenditure, and government initiatives and various NGO’s creating awareness regarding the Hepatitis C treatment is expected to fuel the market growth over the forecast period. In addition, rise in the funding in research and development activities for Hepatitis C treatment and strong pipeline products might boost the global Hepatitis C treatment market over the forecast period. However, lack of antibiotics in the market, high cost of medications, and lack of hepatitis C infection awareness in poor countries might hamper the growth of global Hepatitis C treatment market over the forecast period.



Hepatitis C treatment market segmented on the basis of drug class, route of administration, and distribution channel



Based on drug class, the hepatitis C treatment market has been segmented into the following:

Polymerase Inhibitors
NS5A Inhibitors
Interferons
HCV protease inhibitors
Combination Therapy


Based on route of administration, the hepatitis C treatment market has been segmented into the following:

Oral
Parenteral


Based on distribution channel, the hepatitis C treatment market has been segmented into the following:

Retail Pharmacies
Hospital Pharmacies
Others


Increase in prevalence of hepatitis C infection and liver cirrhosis expected to fuel the growth of Hepatitis C treatment market. According to the World Health Organization WHO, globally there are 80 Mn people suffers from chronic hepatitis C virus, in that approximately 700,000 will die each year as a result of the infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their market share in global hepatitis C treatment market. For instance, in July 2011, Merck MSD, inked an agreement with Roche for the marketing approvals of Victreli Boceprevir triple combination therapy with peginterferon alfa and ribavirin peg/riba. In addition, in August 2011, Vertex Pharmaceuticals Incorporated announced that Health Canada approved its Incivektm Telaprevir tablets for people with genotype 1 chronic hepatitis C with compensated liver disease. In January 2014, European Commission EC granted marketing authorization for Gilead’s Sovaldi Sofosbuvir to treat chronic hepatitis C infection.



Geographically, the hepatitis C treatment market has been segmented into following regions Viz. North America, Europe, AsiaPacific, Latin America, and Middle East & Africa. North America is expected to dominate the global hepatitis C treatment market followed by Europe and AsiaPacific. Increase in prevalence of hepatitis C infection according to Centres for Disease Prevention and Control CDC, approximately 2.73.9 Mn people in the United States are chronically infected with hepatitis C Virus, rise in the awareness among the key stakeholders towards the use of novel products and technologies to treat the hepatitis C, and increase in research and development activities are the key factors bolster the hepatitis C treatment market in North America region. Europe holds a key share in hepatitis C treatment market owing to increase in prevalence of Hepatitis C infection according to European centre for Disease Prevention and Control approximately 5.9 Mn people are suffering from HCV infection, rise in the geriatric population, change in the lifestyle, people involving in the unprotected sexual intercourse, and increase in the research and development activities might boost the hepatitis C treatment market in Europe region. AsiaPacific hepatitis C treatment market growth is attributed to increase in the prevalence of hepatitis C infection, rise in the population in AsiaPacific region, and increase in the healthcare infrastructure. The Middle East & Africa region has high prevalence of HCV infection majorly in Egypt that is approximately 8434 prevalent cases per 100,000 people.



Some of the players in Hepatitis C treatment market are GlaxoSmithKline, plc. U.K., BristolMyers Squibb U.S, F. Hoffmann La Roche Ltd. Switzerland, Merck & Co, Inc. U.S, Johnson & Johnson Services, Inc. U.S., Gilead Sciences U.S., AbbVie Inc. U.S., Vertex Pharmaceuticals Inc. U.S., and Kadmon Holdings, Inc. U.S. to name a few.



In August 2018, AbbVie received FDA approval for Mavyret glecaprevir/pibrentasvir, for the chronic hepatitis C virus HCV infection in all major genotypes GT16


In July 2018, Gilead Sciences, Inc. received U.S. FDA approval for Vosevi used in retreatment of the chronic hepatitis C virus HCV infection


In May 2015, BristolMyers Squibb received U.S. FDA breakthrough therapy designation for investigational drug Daclatasvirbased hepatitis C regimen
1. Executive Summary
2. Global Hepatitis C Treatment Market Introduction
2.1. Global Hepatitis C Treatment Market – Taxonomy
2.2. Global Hepatitis C Treatment Market –Definitions
2.2.1. Drug Class
2.2.2. Route of Administration
2.2.3. Distribution Channel
3. Global Hepatitis C Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hepatitis C Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Hepatitis C Treatment Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
4. Global Hepatitis C Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
4.2. YearoverYear YoY Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Hepatitis C Market, By Drug Class, 2013 2017 and Forecast, 2018 2024
5.1. Polymerase Inhibitors
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. NS5A Inhibitors
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Interferons
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
5.4. HCV protease inhibitors
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.4.3. Market Opportunity Analysis
5.5. Combination Therapy
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.5.3. Market Opportunity Analysis
6. Global Hepatitis C Treatment Market Forecast, By Route of Administration, 2013 2017 and Forecast, 2018 2024
6.1. Oral
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
7. Global Hepatitis C Treatment Market Forecast, By Distribution Channel, 2013 2017 and Forecast, 2018 2024
7.1. Retail Pharmacies
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
8. Global Hepatitis C Treatment Market Forecast, By Region, 2013 2017 and Forecast, 2018 2024
8.1. North America
8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. AsiaPacific
8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.5.3. Market Opportunity Analysis
8.6. Global Hepatitis C Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024
9. North America Hepatitis C Treatment Market Analysis, 2013 2017 and Forecast, 2018 2024
9.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.1.1. Polymerase Inhibitors
9.1.2. NS5A Inhibitors
9.1.3. Interferons
9.1.4. HCV protease inhibitors
9.1.5. Combination Therapy
9.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
9.2.1. Oral
9.2.2. Parenteral

9.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Others
9.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
9.4.1. U.S.
9.4.2. Canada
9.5. North America Hepatitis C Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
9.6. North America Hepatitis C Treatment Market Dynamics – Trends
10. Europe Hepatitis C Treatment Market Analysis, 2013 2017 and Forecast, 2018 2024
10.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.1.1. Polymerase Inhibitors
10.1.2. NS5A Inhibitors
10.1.3. Interferons
10.1.4. HCV protease inhibitors
10.1.5. Combination Therapy
10.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
10.2.1. Oral
10.2.2. Parenteral
10.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Others
10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Hepatitis C Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
10.6. Europe Hepatitis C Treatment Market Dynamics – Trends
11. AsiaPacific Hepatitis C Treatment Market Analysis, 2013 2017 and Forecast, 2018 2024
11.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.1.1. Polymerase Inhibitors
11.1.2. NS5A Inhibitors
11.1.3. Interferons
11.1.4. HCV protease inhibitors
11.1.5. Combination Therapy
11.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
11.2.1. Oral
11.2.2. Parenteral
11.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Others
11.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn,
YoY Growth %, and Market Share %
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of AsiaPacific
11.5. AsiaPacific Hepatitis C Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
11.6. AsiaPacific Hepatitis C Treatment Market Dynamics – Trends
12. Latin America Hepatitis C Treatment Market Analysis, 2013 2017 and Forecast, 2018 2024
12.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.1.1. Polymerase Inhibitors
12.1.2. NS5A Inhibitors
12.1.3. Interferons
12.1.4. HCV protease inhibitors
12.1.5. Combination Therapy
12.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
12.2.1. Oral
12.2.2. Parenteral
12.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Others
12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Hepatitis C Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
12.6. Latin America Hepatitis C Treatment Market Dynamics – Trends
13. Middle East and Africa Hepatitis C Treatment Market Analysis, 2013 2017 and Forecast, 2018 2024
13.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.1.1. Polymerase Inhibitors
13.1.2. NS5A Inhibitors
13.1.3. Interferons
13.1.4. HCV protease inhibitors
13.1.5. Combination Therapy
13.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
13.2.1. Oral
13.2.2. Parenteral
13.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Others
13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.4.1. Gulf Cooperation Council GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Hepatitis C Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
13.6. MEA Hepatitis C Treatment Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis
14.2.1. GlaxoSmithKline, plc. U.K.
14.2.2. BristolMyers Squibb U.S
14.2.3. F. Hoffmann La Roche Ltd. Switzerland
14.2.4. Merck & Co, Inc. U.S
14.2.5. Johnson & Johnson Services, Inc. U.S.
14.2.6. Gilead Sciences U.S.
14.2.7. AbbVie Inc. U.S.
14.2.8. Vertex Pharmaceuticals Inc. U.S.
14.2.9. Kadmon Holdings, Inc. U.S.
15. Research Methodology
16. Key Assumptions and Acronyms
  Purchase Options for Report

Need More information

Call us :
USA : +1 7162260907
UK : +44 7441952057
....
sales@planetmarketreports.com

Why to PMR

PMR Market Research

Our syndicated research reports cover 50+ industry sectors offering you product and country wise breakup of the market along with niche data and insights that will help you make informed business decision. Our research is focused on the key segments of an industry that possess opportunities of growth.

  • Industrial ...
  • Business ....
  • Consumer ....
  • Peer ....